| 摘要 |
The invention relates to arylpyrazine compounds, including arylpyrazines that can bind with high affinity and high selectivity to CRF1 receptors, including human CRF1 receptors. The invention relatesalso to methods for treatment of disorders and diseases associated with CRF1 receptors, including CNS-related disorders and diseases, particularly maniacal-depressive disorders and diseases, as well as acute and chronic neurological disorders and diseases. |
